Mirabilis Completes First
Human Trial of Non-Invasive Treatment for Uterine Fibroids
BOTHELL WA, April
28, 2008
Mirabilis Medica, a privately-held medical
device company, today announced completion of its first human
trial, which served as a preliminary demonstration of clinical
feasibility of its prototype High Intensity Focused Ultrasound
(HIFU) system for treatment of uterine fibroids. Volunteer
patients were treated with the Mirabilis system just prior
to scheduled hysterectomies, after which the excised uterine
tissue was examined by a pathologist for effects of treatment.
This analysis demonstrated successful creation of lesions within
the target zone.
“We are encouraged by this early clinical
feedback, which is an important milestone in Mirabilis' path
to developing a commercial product. We continue to develop
several advanced features in preparation for future efficacy
studies in patients with fibroids," said Mirabilis CEO Mike
Connolly.
About Uterine Fibroids
Fibroids are extremely common benign tumors of the uterus
which can substantially impact quality of life. Symptoms can
include heavy or prolonged menstrual bleeding, pelvic cramps,
urinary frequency or urgency, and pregnancy loss or infertility.
An estimated 25% of women (16 million in the U.S.) suffer fibroid
symptoms at some point in their life, leading to 250,000 annual
U.S. hysterectomies – a highly invasive surgery with
many side effects.
About Mirabilis
Medica
Mirabilis Medica, based in Bothell WA, was founded in
2004 by Michael Lau, M.D., FACS, FACOG, Alexander Lebedev,
and Shahram Vaezy, Ph.D. Mirabilis’ patented technology
combines the application of therapeutic ultrasound (i.e. HIFU)
under real-time guidance of imaging ultrasound. This leading-edge
technology is designed to allow a physician to treat pathological
tissue deep inside the body without incisions, punctures or
other damage to intervening tissue.
For more information, see www.mirabilismedica.com
|
